The productivity crisis in pharmaceutical R&D

Citations

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:

1. Why so few drug innovations?
   by Economic Logician in Economic Logic on 2010-09-02 19:25:00

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

as

HTML HTML with abstract plain text plain text with abstract BibTeX RIS (EndNote, RefMan, ProCite) ReDIF JSON

Cited by:

1. Francesco Fallucchi & Jan Niederreiter & Massimo Riccaboni, 2021. "Learning and dropout in contests: an experimental approach," Theory and Decision, Springer, vol. 90(2), pages 245-278, March.
2. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
3. Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(13), pages 1-15, July.
4. Martin Backfisch, 2017. "Have Pharmaceutical R&D Project Success Rates Decreased? A Critical Review and New Empirical Results," MAGKS Papers on Economics 201746, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
5. Tommaso Ciarli & André Lorentz & Marco Valente & Maria Savona, 2019. "Structural changes and growth regimes," Journal of Evolutionary Economics, Springer, vol. 29(1), pages 119-176, March.
   • Tommaso Ciarli & Andre Lorentz & Marco Valente & Mario Savona, 2017. "Structural Changes and Growth Regimes," SPRU Working Paper Series 2017-12, SPRU - Science Policy Research Unit, University of Sussex Business School.
   • Tommaso Ciarli & Andre Lorentz & Marco Tulio Valente & Maria Savona, 2019. "Structural changes and growth regimes," Post-Print hal-02180398, HAL.
   • Tommaso Ciarli & Andre Lorentz & Marco Valente & Maria Savona, 2017. "Structural Changes and Growth Regime," Working Papers of BETA 2017-19, Bureau d'Economie Théorique et Appliquée, UDS, Strasbourg.
6. Lorenz, Steffi, 2015. "Diversität und Verbundenheit der unternehmerischen Wissensbasis: Ein neuartiger Messansatz mit Indikatoren aus Innovationsprojekten," Discussion Papers on Strategy and Innovation 15-01, Philipps-University Marburg, Department of Technology and Innovation Management (TIM).
7. Changhyeon Song & Kwangsoo Shin, 2019. "Business Model Design for Latecomers in Biopharmaceutical Industry: The Case of Korean Firms," Sustainability, MDPI, vol. 11(18), pages 1-15, September.
8. Jakub Growiec & Fabio Pammolli & Massimo Riccaboni, 2020. "Innovation and Corporate Dynamics: A Theoretical Framework," Central European Journal of Economic Modelling and Econometrics, Central European Journal of Economic Modelling and Econometrics, vol. 12(1), pages 1-45, March.
   • Jakub Growiec & Fabio Pammolli & Massimo Riccaboni, 2011. "Innovation and Corporate Dynamics: A Theoretical Framework," DISA Working Papers 2011/08, Department of Computer and Management Sciences, University of Trento, Italy, revised 29 Jul 2011.
   • Massimo, Riccaboni & Jakub, Growiec & Fabio, Pammolli, 2011. "Innovation and Corporate Dynamics: A Theoretical Framework," MPRA Paper 30046, University Library of Munich, Germany.
9. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
10. Martin Backfisch, 2018. "The Development of Firm Size and Innovativeness in the Pharmaceutical industry between 1989 and 2010," MAGKS Papers on Economics 201813, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
11. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017. "The Dynamics of Pharmaceutical Regulation and R&D Investments," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.
    • Rosella Levaggi & Michele Moretto & Paolo Pertile, 2013. "The dynamics of pharmaceutical regulation and R&D investments," Working Papers 13/2013, University of Verona, Department of Economics.
12. BELDERBOS, René & GILSING, Victor & SUZUKI, Shinya, 2015. "Direct And Mediated Ties To Universities: ‘Scientific’ Absorptive Capacity And Innovation Performance Of Pharmaceutical Firms," Discussion paper series 2015-06, Hitotsubashi Institute for Advanced Study, Hitotsubashi University.
    • Rene Belderbos & Victor Gilsing & Shinya Suzuki, 2015. "Direct and mediated ties to universities: ‘Scientific’ absorptive capacity and innovation performance of pharmaceutical firms," Working Papers of Department of Management, Strategy and Innovation, Leuven 504836, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
13. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    • Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
    • Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
    • Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
    • Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
14. Jing-Yuan Chio & Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2012. "The Value of Failures in Pharmaceutical R&D," Working Papers 1/2012, IMT School for Advanced Studies Lucca, revised Jan 2012.
15. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
16. Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2012. "I Farmaci Oncologici in Italia: innovazione e sostenibilità economica," Working Papers CERM 02-2012, Competitività, Regole, Mercati (CERM).
17. Massimo Riccaboni, 2012. "Is There a Productivity Crisis in Pharmaceutical R&D?," Seminar Briefing 000146, Office of Health Economics.
18. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
    • Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
19. Jing-Yuan Chiou & Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2016. "Learning from successes and failures in pharmaceutical R&D," Journal of Evolutionary Economics, Springer, vol. 26(2), pages 271-290, May.
20. Kaustav Das & Nicolas Klein, 2020. "Do Stronger Patents Lead to Faster Innovation? The Effect of Duplicative Search," Discussion Papers in Economics 20/03, Division of Economics, School of Business, University of Leicester.
21. Jinhee Kwon & Cheong Kim & Kun Chang Lee, 2020. "Moderating Effect of the Continental Factor on the Business Strategy and M&A Performance in the Pharmaceutical Industry for Sustainable International Business," Sustainability, MDPI, vol. 12(12), pages 1-14, June.
22. Zuo-Qi Ding & Jian-Ping Ge & Xiao-Ming Wu & Xiao-Nan Zheng, 2013. "Bibliometrics evaluation of research performance in pharmacology/pharmacy: China relative to ten representative countries," Scientometrics, Springer;Akadémiai Kiadó, vol. 96(3), pages 829-844, September.
23. Jörg Mahlich & Arne Bartol & Srirangan Dheban, 2021. "Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis," Health Economics Review, Springer, vol. 11(1), pages 1-10, December.
24. Heyoung Yang & Hyuck Jai Lee, 2018. "Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry," Sustainability, MDPI, vol. 10(2), pages 1-14, January.
25. Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.
26. Alexandre Trigo, 2016. "Innovation in the Era of Experience: The Changing Role of Users in Healthcare Innovation," Journal of Entrepreneurship, Management and Innovation, Fundacja Upowszechniająca Wiedzę i Naukę "Cognitione", vol. 12(2), pages 29-51.
27. Magazzini Laura & Fabio Pammolli & Massimo Riccaboni, 2013. "R&D, Within and Between Patent Competition in the Pharmaceutical Industry," Working Papers 3/2013, IMT School for Advanced Studies Lucca, revised Jul 2013.
28. Fabio Pammolli & Paolo Bonaretti & Massimo Riccaboni & Valentina Tortolini, 2019. "Quali Regole per la Spesa Farmaceutica? - Criticità, Impatti, Proposte," Working Papers CERM 01-2019, Competitività, Regole, Mercati (CERM).